Brand name: Istodax®
Manufactured by Celgene
HDAC inhibitors target DNA associated proteins (histones) and allow the cell’s genes to be transcribed or expressed in a way that may help cancer cells die.
Romidepsin has been FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. It is also a histone deacetylase (HDAC) inhibitor. Romidepsin is given as an intravenous infusion over four hours every week for three weeks and then one week of rest. The side effects of romidepsin are similar to other HDAC inhibitors such as vorinostat. Blood tests to check the level of magnesium and potassium may be performed before the drug is given.
More information about Istodax may be found at: www.istodax.com
More information about Celgene Patient Support may be found at: www.celgenepatientsupport.com
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.